Elite Pharmaceuticals, Inc. announced results for the second quarter of fiscal year 2026, showing significant growth in revenues and income from operations.
Consolidated revenues for the three-month period ending September 30, 2025, were $36.3 million, representing a 92% increase compared to the prior fiscal year.
Income from operations reached $8.2 million, marking a 136% increase compared to the prior fiscal year.
Revenue Growth
Consolidated revenues increased by 92% year-over-year, driven by strong sales of Elite's products.
Income Performance
Income from operations surged by 136% year-over-year, primarily due to sales of lisdexamfetamine products.
Product Line Expansion
Elite's product lines include immediate-release and controlled-release oral dose products marketed under Elite Laboratories label.
- The strong financial performance reflects Elite Pharmaceuticals' successful niche generic product development strategy.
- Sales growth in lisdexamfetamine products and overall label product lines contributed significantly to the increase in income from operations.
With a robust financial performance in Q2, Elite Pharmaceuticals demonstrates its ability to drive growth and capture market share in the specialty pharmaceutical industry.